148 related articles for article (PubMed ID: 37816291)
21. The BRAF p.V600E mutation is a common event in ameloblastomas but is absent in odontogenic keratocysts.
Zhang R; Yang Q; Qu J; Hong Y; Liu P; Li T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Mar; 129(3):229-235. PubMed ID: 31987674
[TBL] [Abstract][Full Text] [Related]
22. BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response.
Tan S; Pollack JR; Kaplan MJ; Colevas AD; West RB
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Jul; 122(1):e5-7. PubMed ID: 27209484
[TBL] [Abstract][Full Text] [Related]
23. High prevalence of BRAF V600E mutations in Korean patients with ameloblastoma: Clinicopathological significance and correlation with epithelial-mesenchymal transition.
Oh KY; Cho SD; Yoon HJ; Lee JI; Ahn SH; Hong SD
J Oral Pathol Med; 2019 May; 48(5):413-420. PubMed ID: 30889301
[TBL] [Abstract][Full Text] [Related]
24. Genomic profiling and precision medicine in complex ameloblastoma.
Gates JC; Clark AP; Cherkas E; Shreenivas AV; Kraus D; Danzinger N; Huang RSP; Johnson J; Ross JS
Head Neck; 2023 Apr; 45(4):816-826. PubMed ID: 36645099
[TBL] [Abstract][Full Text] [Related]
25. BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature.
Ebeling M; Scheurer M; Sakkas A; Pietzka S; Schramm A; Wilde F
Med Oncol; 2023 Apr; 40(6):163. PubMed ID: 37115331
[TBL] [Abstract][Full Text] [Related]
26. High frequency of BRAF V600E mutation in Iranian population ameloblastomas.
Derakhshan S; Aminishakib P; Karimi A; Saffar H; Abdollahi A; Mohammadpour H; Kharazi Fard MJ; Memarha A
Med Oral Patol Oral Cir Bucal; 2020 Jul; 25(4):e502-e507. PubMed ID: 32388526
[TBL] [Abstract][Full Text] [Related]
27. BRAF-V600E expression correlates with ameloblastoma aggressiveness.
Fregnani ER; Perez DE; Paes de Almeida O; Fonseca FP; Soares FA; Castro-Junior G; Alves FA
Histopathology; 2017 Feb; 70(3):473-484. PubMed ID: 27681305
[TBL] [Abstract][Full Text] [Related]
28. The Role of BRAF Inhibitors in the Management of Ameloblastoma: A Literature Review.
Malakar A; Kumar VR; Yadav P; Bhardwaj V; Barua CG; Bhardwaj G
Cureus; 2023 Oct; 15(10):e47682. PubMed ID: 38021761
[TBL] [Abstract][Full Text] [Related]
29. Novel targets for the treatment of ameloblastoma.
Heikinheimo K; Kurppa KJ; Elenius K
J Dent Res; 2015 Feb; 94(2):237-40. PubMed ID: 25425580
[No Abstract] [Full Text] [Related]
30. Ameloblastoma: A succinct review of the classification, genetic understanding and novel molecular targeted therapies.
Shi HA; Ng CWB; Kwa CT; Sim QXC
Surgeon; 2021 Aug; 19(4):238-243. PubMed ID: 32712102
[TBL] [Abstract][Full Text] [Related]
31. The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma.
Mendez LD; Wolsefer NS; Asa SL; Wasman J; Yoest JM; Stojanov IJ
Mod Pathol; 2022 Nov; 35(11):1570-1577. PubMed ID: 35676332
[TBL] [Abstract][Full Text] [Related]
32. BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution.
Owosho AA; Ladeji AM; Adebiyi KE; Olajide MA; Okoye ISI; Kehinde T; Nwizu NN; Summersgill KF
Eur Arch Otorhinolaryngol; 2021 Aug; 278(8):3065-3071. PubMed ID: 33231757
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas.
do Canto AM; da Silva Marcelino BMR; Schussel JL; Wastner BF; Sassi LM; Corrêa L; de Freitas RR; Hasséus B; Kjeller G; Junior CAL; Braz-Silva PH
Clin Oral Investig; 2019 Feb; 23(2):779-784. PubMed ID: 29855709
[TBL] [Abstract][Full Text] [Related]
34. K-Ras gene status and expression of Ras/mitogen-activated protein kinase (MAPK) signaling molecules in ameloblastomas.
Kumamoto H; Takahashi N; Ooya K
J Oral Pathol Med; 2004 Jul; 33(6):360-7. PubMed ID: 15200485
[TBL] [Abstract][Full Text] [Related]
35. Correlation of BRAF mutational status with clinical characteristics and survival outcomes of patients with ameloblastoma: the experience of 11 Italian centres.
Bonacina R; Indini A; Massazza G; Rulli E; Gianatti A; Mandalà M;
J Clin Pathol; 2022 Aug; 75(8):555-559. PubMed ID: 33827932
[TBL] [Abstract][Full Text] [Related]
36. Molecular pathogenesis of ameloblastoma.
Marín-Márquez C; Kirby J; Hunter KD
J Oral Pathol Med; 2024 May; 53(5):277-293. PubMed ID: 38664938
[TBL] [Abstract][Full Text] [Related]
37. Genetic Study of
Kokubun K; Yamamoto K; Akashi Y; Chujo T; Nakajima K; Matsuzaka K
Int J Surg Pathol; 2022 Jun; 30(4):378-384. PubMed ID: 34994576
[No Abstract] [Full Text] [Related]
38. Ameloblastoma-Clinical, radiological, and therapeutic findings.
Kreppel M; Zöller J
Oral Dis; 2018 Mar; 24(1-2):63-66. PubMed ID: 29480593
[TBL] [Abstract][Full Text] [Related]
39. Ameloblastoma with mucous cells: A clinicopathological, BRAF mutation, and MAML2 rearrangement study.
Xia RH; Zhang CY; Sun JJ; Tian Z; Hu YH; Gu T; Wang LZ; Li J
Oral Dis; 2020 May; 26(4):805-814. PubMed ID: 31954088
[TBL] [Abstract][Full Text] [Related]
40. Discrepancy between immunohistochemistry and sequencing for BRAF V600E in odontogenic tumours: Comparative analysis of two VE1 antibodies.
Oh KY; Cho SD; Yoon HJ; Lee JI; Hong SD
J Oral Pathol Med; 2021 Jan; 50(1):85-91. PubMed ID: 32939809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]